Ramiro Sanchez - 26 Dec 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
26 Dec 2023
Net transactions value
-$389,700
Form type
4
Filing time
28 Dec 2023, 16:15:10 UTC
Previous filing
21 Dec 2023
Next filing
23 Jan 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $35,000 +10,000 +68% $3.50* 24,673 26 Dec 2023 Direct F1
transaction CERE Common Stock Sale $424,700 -10,000 -41% $42.47 14,673 26 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -10,000 -1.8% $0.000000 538,435 26 Dec 2023 Common Stock 10,000 $3.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person.
F2 The option is fully vested and exercisable.